PE20211498A1 - Anticuerpos dirigidos contra il-11 - Google Patents
Anticuerpos dirigidos contra il-11Info
- Publication number
- PE20211498A1 PE20211498A1 PE2020001992A PE2020001992A PE20211498A1 PE 20211498 A1 PE20211498 A1 PE 20211498A1 PE 2020001992 A PE2020001992 A PE 2020001992A PE 2020001992 A PE2020001992 A PE 2020001992A PE 20211498 A1 PE20211498 A1 PE 20211498A1
- Authority
- PE
- Peru
- Prior art keywords
- cdrs
- chain variable
- variable region
- binding
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a una molecula de union a antigeno capaz de unirse a interleucina 11 (IL-11), donde la molecula de union a antigeno comprende: (i) una region variable de cadena pesada (VH) que comprende CDRs de secuencias SED ID NO: 37, 38 y 40; y (ii) una region variable de cadena ligera (VL) que comprende CDRs de secuencias SEQ ID NO: 42, 45 y 81; o (i) una region variable de cadena pesada (VH) que comprende CDRs de secuencias SED ID NO: 37, 38 y 40; y (ii) una region variable de cadena ligera (VL) que comprende CDRs de secuencias SEQ ID NO: 42, 45 y 57; o (i) una region variable de cadena pesada (VH) que comprende CDRs de secuencias SED ID NO: 95, 96 y 97; y (ii) una region variable de cadena ligera (VL) que comprende CDRs de secuencias SEQ ID NO: 101, 102 y 103. Tambien se refiere a un receptor de antigeno quimerico (CAR) que comprende la molecula de union a IL-11, acidos nucleicos, un vector, una celula, un metodo que comprende cultivar dicha celula, una composicion, un kit y un metodo para inhibir la senalizacion mediada por IL-11 que comprende poner en contacto celulas que expresan IL-11 con la molecula de union a IL-11 de la invencion. Dichas moleculas de union a IL-11 son utiles en el tratamiento medico o profilaxis de una enfermedad caracterizada por fibrosis, cancer, inflamacion, hepatotoxicidad, enfermedad metabolica, nefrotoxicidad, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1809699.0A GB201809699D0 (en) | 2018-06-13 | 2018-06-13 | IL-11 antibodies |
| PCT/EP2019/065598 WO2019238882A1 (en) | 2018-06-13 | 2019-06-13 | Il-11 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211498A1 true PE20211498A1 (es) | 2021-08-11 |
Family
ID=63042160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001992A PE20211498A1 (es) | 2018-06-13 | 2019-06-13 | Anticuerpos dirigidos contra il-11 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11084874B2 (es) |
| EP (1) | EP3807314A1 (es) |
| JP (1) | JP2021535733A (es) |
| KR (1) | KR20210031690A (es) |
| CN (1) | CN113056481A (es) |
| AU (1) | AU2019286795A1 (es) |
| BR (1) | BR112020025443A2 (es) |
| CA (1) | CA3102483A1 (es) |
| CL (1) | CL2020003223A1 (es) |
| CO (1) | CO2020015383A2 (es) |
| CR (1) | CR20210009A (es) |
| DO (1) | DOP2020000245A (es) |
| EA (1) | EA202092668A1 (es) |
| EC (1) | ECSP21000695A (es) |
| GB (1) | GB201809699D0 (es) |
| IL (1) | IL279356A (es) |
| JO (1) | JOP20200309A1 (es) |
| MA (1) | MA52884A (es) |
| MX (1) | MX2020013583A (es) |
| PE (1) | PE20211498A1 (es) |
| PH (1) | PH12020552232A1 (es) |
| SG (1) | SG11202011782XA (es) |
| TW (1) | TW202003560A (es) |
| WO (1) | WO2019238882A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| MX2019007020A (es) | 2016-12-16 | 2019-10-21 | Singapore Health Serv Pte Ltd | Anticuerpos il-11. |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| TW202043276A (zh) | 2019-01-21 | 2020-12-01 | 新加坡商新加坡保健服務私人有限公司 | 肝毒性之治療 |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| US11813311B2 (en) | 2019-05-03 | 2023-11-14 | Singapore Health Services Pte Ltd. | Treatment and prevention of metabolic diseases |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| EP4181959A1 (en) * | 2020-07-20 | 2023-05-24 | Integrated BioTherapeutics, Inc. | Broadly neutralizing binding molecules against marburgviruses |
| EP4198055A1 (en) * | 2020-08-13 | 2023-06-21 | Sunshine Lake Pharma Co., Ltd. | Antibody of il-11 and use thereof |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| CN113980129B (zh) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | 一组il-11单克隆抗体及其医药用途 |
| EP4298123A2 (en) | 2021-02-26 | 2024-01-03 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
| EP4376948A1 (en) | 2021-07-26 | 2024-06-05 | Boehringer Ingelheim International GmbH | Treatment and prevention of alcoholic liver disease |
| WO2023016505A1 (zh) * | 2021-08-12 | 2023-02-16 | 广东东阳光药业有限公司 | Il-11人源化抗体及其应用 |
| WO2023111196A1 (en) | 2021-12-16 | 2023-06-22 | Singapore Health Services Pte. Ltd. | Treatment and prevention of glomerular disease |
| WO2023143556A1 (zh) * | 2022-01-29 | 2023-08-03 | 迈威(上海)生物科技股份有限公司 | 一种抗白介素-11的抗体及其应用 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332579A3 (en) * | 2000-02-10 | 2011-09-21 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| US8518888B2 (en) * | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| MX2019007020A (es) * | 2016-12-16 | 2019-10-21 | Singapore Health Serv Pte Ltd | Anticuerpos il-11. |
| RU2016151730A (ru) | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
-
2018
- 2018-06-13 GB GBGB1809699.0A patent/GB201809699D0/en not_active Ceased
-
2019
- 2019-06-13 US US16/440,840 patent/US11084874B2/en active Active
- 2019-06-13 JO JOP/2020/0309A patent/JOP20200309A1/ar unknown
- 2019-06-13 PE PE2020001992A patent/PE20211498A1/es unknown
- 2019-06-13 CN CN201980054506.1A patent/CN113056481A/zh active Pending
- 2019-06-13 SG SG11202011782XA patent/SG11202011782XA/en unknown
- 2019-06-13 TW TW108120516A patent/TW202003560A/zh unknown
- 2019-06-13 MX MX2020013583A patent/MX2020013583A/es unknown
- 2019-06-13 WO PCT/EP2019/065598 patent/WO2019238882A1/en active Application Filing
- 2019-06-13 EP EP19734285.0A patent/EP3807314A1/en active Pending
- 2019-06-13 KR KR1020217000825A patent/KR20210031690A/ko unknown
- 2019-06-13 CR CR20210009A patent/CR20210009A/es unknown
- 2019-06-13 CA CA3102483A patent/CA3102483A1/en active Pending
- 2019-06-13 MA MA052884A patent/MA52884A/fr unknown
- 2019-06-13 AU AU2019286795A patent/AU2019286795A1/en active Pending
- 2019-06-13 JP JP2020568955A patent/JP2021535733A/ja active Pending
- 2019-06-13 EA EA202092668A patent/EA202092668A1/ru unknown
- 2019-06-13 BR BR112020025443-6A patent/BR112020025443A2/pt unknown
-
2020
- 2020-12-09 CO CONC2020/0015383A patent/CO2020015383A2/es unknown
- 2020-12-10 IL IL279356A patent/IL279356A/en unknown
- 2020-12-11 CL CL2020003223A patent/CL2020003223A1/es unknown
- 2020-12-11 DO DO2020000245A patent/DOP2020000245A/es unknown
- 2020-12-13 PH PH12020552232A patent/PH12020552232A1/en unknown
-
2021
- 2021-01-06 EC ECSENADI2021695A patent/ECSP21000695A/es unknown
- 2021-03-25 US US17/212,456 patent/US20210230266A1/en active Pending
-
2024
- 2024-03-01 US US18/592,665 patent/US20240190953A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3102483A1 (en) | 2019-12-19 |
| ECSP21000695A (es) | 2021-03-31 |
| CN113056481A (zh) | 2021-06-29 |
| SG11202011782XA (en) | 2020-12-30 |
| MA52884A (fr) | 2021-04-21 |
| AU2019286795A1 (en) | 2021-01-28 |
| KR20210031690A (ko) | 2021-03-22 |
| US20200031918A1 (en) | 2020-01-30 |
| DOP2020000245A (es) | 2021-10-31 |
| US20240190953A1 (en) | 2024-06-13 |
| MX2020013583A (es) | 2021-04-13 |
| CO2020015383A2 (es) | 2021-04-19 |
| JP2021535733A (ja) | 2021-12-23 |
| WO2019238882A1 (en) | 2019-12-19 |
| US20210230266A1 (en) | 2021-07-29 |
| EP3807314A1 (en) | 2021-04-21 |
| CR20210009A (es) | 2021-06-21 |
| EA202092668A1 (ru) | 2021-05-18 |
| CL2020003223A1 (es) | 2021-07-30 |
| TW202003560A (zh) | 2020-01-16 |
| BR112020025443A2 (pt) | 2021-03-16 |
| IL279356A (en) | 2021-01-31 |
| US11084874B2 (en) | 2021-08-10 |
| JOP20200309A1 (ar) | 2020-11-30 |
| PH12020552232A1 (en) | 2021-06-28 |
| GB201809699D0 (en) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211498A1 (es) | Anticuerpos dirigidos contra il-11 | |
| PE20211500A1 (es) | Anticuerpos dirigidos contra il-11ra | |
| AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
| CL2011000632A1 (es) | Anticuerpo humanizado anti-receptor de interleuquina 6 (il-6); regiones variables y cadenas pesadas o livianas de los mismos; secuencia nucleotídica que lo codifica; vector; célula huésped; método de producción; y composición farmacéutica que lo comprende. | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| AR110979A1 (es) | Moléculas de unión a cd70 y métodos de uso de las mismas | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| CL2008002349A1 (es) | Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. | |
| AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
| JP2017511130A5 (es) | ||
| PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| AR065420A1 (es) | Anticuerpos anti-il-23 p19 de ingenieria | |
| CL2009001001A1 (es) | Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares. | |
| AR062213A1 (es) | Anticuerpos dirigidos contra (alfa v beta 6) y usos de los mismos | |
| AR116564A1 (es) | Moléculas de unión a antígeno biespecíficas con unión trivalente a cd40 | |
| PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| AR072167A1 (es) | Anticuerpos contra il-6 humano y sus usos |